Charles River Laboratories International, Inc. Share Price
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171.95 USD | -2.85% |
|
-2.09% | -13.76% |
| Capitalization | 8.71B 7.52B 6.79B 6.5B 11.82B 803B 12.36B 80.13B 32.13B 384B 32.71B 32B 1,378B | P/E ratio 2026 * |
22.7x | P/E ratio 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise value | 8.71B 7.52B 6.79B 6.5B 11.82B 803B 12.36B 80.13B 32.13B 384B 32.71B 32B 1,378B | EV / Sales 2026 * |
2.26x | EV / Sales 2027 * | 2.24x |
| Free-Float |
97.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | -2.78% | ||
| 1 week | -2.09% | ||
| Current month | -3.62% | ||
| 1 month | -5.08% | ||
| 3 months | -11.71% | ||
| 6 months | +12.24% | ||
| Current year | -13.76% |
| 1 week | 166.82 | 182.65 | |
| 1 month | 146.33 | 183.11 | |
| Current year | 146.33 | 228.88 | |
| 1 year | 91.86 | 228.88 | |
| 3 years | 91.86 | 275 | |
| 5 years | 91.86 | 460.21 | |
| 10 years | 67.2 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 75 | 31/12/1991 |
Michael Knell
DFI | Director of Finance/CFO | 49 | 28/09/2025 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 11/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 31/12/1999 |
Martin MacKay
BRD | Director/Board Member | 69 | 04/07/2017 |
Virginia Wilson
BRD | Director/Board Member | 70 | 30/09/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.85% | -2.09% | -1.77% | -15.07% | 8.71B | ||
| +0.60% | -3.36% | -7.98% | -6.22% | 44.96B | ||
| +1.93% | +3.54% | +26.75% | +42.24% | 33.54B | ||
| +0.98% | -13.63% | +16.43% | +43.10% | 30.24B | ||
| -2.71% | -0.08% | -7.92% | -11.88% | 29.97B | ||
| +0.47% | -0.55% | +171.43% | +381.41% | 19.78B | ||
| +0.84% | +0.54% | +74.05% | +126.44% | 14.73B | ||
| -1.49% | +1.76% | +40.36% | +169.95% | 13.58B | ||
| +0.85% | -3.12% | +22.63% | +1.01% | 12.97B | ||
| +1.53% | -3.38% | +135.88% | +123.79% | 12.45B | ||
| Average | +0.08% | -1.65% | +46.99% | +85.48% | 22.09B | |
| Weighted average by Cap. | +0.25% | -1.67% | +35.29% | +68.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.86B 3.33B 3.01B 2.88B 5.24B 356B 5.48B 35.5B 14.24B 170B 14.49B 14.18B 610B | 3.9B 3.36B 3.04B 2.91B 5.29B 359B 5.53B 35.84B 14.37B 172B 14.63B 14.31B 616B |
| Net income | - | - |
| Net Debt | - | - |
Employees
19,000
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/03/26 | 172.28 $ | -2.66% | 217,006 |
| 09/03/26 | 176.99 $ | +1.45% | 1,029,086 |
| 06/03/26 | 174.46 $ | -3.78% | 1,078,851 |
| 05/03/26 | 181.32 $ | +0.97% | 1,145,086 |
| 04/03/26 | 179.58 $ | +2.21% | 742,853 |
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
176.99USD
Average target price
197.47USD
Spread / Average Target
+11.57%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition

















